PEGylated Heterofunctional Dendrimers Enable Multivalent Diclofenac Delivery for ROS-Driven Anticancer Activity

Cancer drug development faces escalating costs and limited success, driving interest toward drug repurposing strategies. Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID) with emerging anticancer potential, exhibits poor aqueous solubility and rapid systemic clearance, limiting its chemotherapeutic suitability. Here, we engineered PEGylated heterofunctional polyester dendrimers (HFDs) as modular nanocarriers that enable controlled multivalent presentation of diclofenac through orthogonal chemistry. Diclofenac was conjugated within the dendritic interior using copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) while peripheral PEGylation was introduced through anhydride esterification. First- and second-generation constructs, G1-(Dicl)<sub>3</sub>-(mPEG)<sub>6</sub> and G2-(Dicl)<sub>9</sub>-(mPEG)<sub>12</sub>, assembled into amphiphilic core-shell nanostructures with hydrodynamic diameters of 170-330 nm and well-defined drug loading. G1-(Dicl)<sub>3</sub>-(mPEG)<sub>6</sub> demonstrated the strongest therapeutic performance, reducing viability by 50-70% in MCF-7, U-87 MG, and PANC-1 cancer cells at 1-10 μM while maintaining >95% viability in noncancerous fibroblasts. This represents a >20-fold improvement in therapeutic index compared to free diclofenac. G2-(Dicl)<sub>9</sub>-(mPEG)<sub>12</sub> displayed potent but cell-line-dependent activity, with highest efficacy in MCF-7 cells. Both dendrimers required 10-100× lower concentrations than free diclofenac to induce comparable reactive oxygen species (ROS) levels, with G1 producing 3-4-fold ROS elevation at 10 μM and G2 achieving similar induction at 0.1 μM. Mechanistic analysis confirmed ROS-mediated cytotoxicity as a key contributing pathway and correlated directly with cytotoxicity across various cancer models. These findings establish HFDs as an adaptable nanomedicine platform for repurposing clinically approved drugs, with G1 dendrimer providing the optimal balance of efficacy, selectivity, and translational potential.

Authors

Institutions

Publication Details

Journal
ACS Applied Materials & Interfaces
Published
2026-02-10
DOI
https://doi.org/10.1021/acsami.6c00115
Primary Topic
Dendrimers and Hyperbranched Polymers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PEGylated Heterofunctional Dendrimers Enable Multivalent Diclofenac Delivery for ROS-Driven Anticancer Activity

Natalia Sanz del Olmo, Arunika Singh, Michael Malkoch
ACS Applied Materials & Interfaces
Dendrimers and Hyperbranched Polymers
article

PEGylated Heterofunctional Dendrimers Enable Multivalent Diclofenac Delivery for ROS-Driven Anticancer Activity

Natalia Sanz del Olmo, Arunika Singh, Michael Malkoch
article en

Abstract

Cancer drug development faces escalating costs and limited success, driving interest toward drug repurposing strategies. Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID) with emerging anticancer potential, exhibits poor aqueous solubility and rapid systemic clearance, limiting its chemotherapeutic suitability. Here, we engineered PEGylated heterofunctional polyester dendrimers (HFDs) as modular nanocarriers that enable controlled multivalent presentation of diclofenac through orthogonal chemistry. Diclofenac was conjugated within the dendritic interior using copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) while peripheral PEGylation was introduced through anhydride esterification. First- and second-generation constructs, G1-(Dicl)<sub>3</sub>-(mPEG)<sub>6</sub> and G2-(Dicl)<sub>9</sub>-(mPEG)<sub>12</sub>, assembled into amphiphilic core-shell nanostructures with hydrodynamic diameters of 170-330 nm and well-defined drug loading. G1-(Dicl)<sub>3</sub>-(mPEG)<sub>6</sub> demonstrated the strongest therapeutic performance, reducing viability by 50-70% in MCF-7, U-87 MG, and PANC-1 cancer cells at 1-10 μM while maintaining >95% viability in noncancerous fibroblasts. This represents a >20-fold improvement in therapeutic index compared to free diclofenac. G2-(Dicl)<sub>9</sub>-(mPEG)<sub>12</sub> displayed potent but cell-line-dependent activity, with highest efficacy in MCF-7 cells. Both dendrimers required 10-100× lower concentrations than free diclofenac to induce comparable reactive oxygen species (ROS) levels, with G1 producing 3-4-fold ROS elevation at 10 μM and G2 achieving similar induction at 0.1 μM. Mechanistic analysis confirmed ROS-mediated cytotoxicity as a key contributing pathway and correlated directly with cytotoxicity across various cancer models. These findings establish HFDs as an adaptable nanomedicine platform for repurposing clinically approved drugs, with G1 dendrimer providing the optimal balance of efficacy, selectivity, and translational potential.

ACS Applied Materials & InterfacesVol. 18(7)
Universidad de Alcalá (ES), Instituto Cajal (ES), Institute of Inorganic Chemistry of the Slovak Academy of Sciences (SK), Instituto Ramón y Cajal de Investigación Sanitaria (ES), KTH Royal Institute of Technology (SE)
Good health and well-being
Openalex Percentile: Top 61%
Dendrimers and Hyperbranched Polymers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.